1. Adelaide Research & Scholarship

Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 101-110 of 171 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2008BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of IkarosMullighan, C.; Miller, C.; Radtke, I.; Philips, L.; Dalton, J.; Ma, J.; White, D.; Hughes, T.; Le Beau, M.; Pui, C.; Relling, M.; Shurtleff, S.; Downing, J.
2001Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two casesHui, C.; Bardy, P.; Hughes, T.; Horvath, N.; To, L.
2002Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneBranford, S.; Hughes, T.; Rudzki, Z.
2001Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemiaLutwyche, J.; Keough, R.; Hughes, T.; Gonda, T.
2009Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapyHughes, T.; Hochhaus, A.
2010Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitorsHiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
2018Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift studyHiwase, D.; Tan, P.; D'Rozario, J.; Taper, J.; Powell, A.; Irving, I.; Wright, M.; Branford, S.; Yeung, D.T.; Anderson, L.; Gervasio, O.; Levetan, C.; Roberts, W.; Solterbeck, A.; Traficante, R.; Hughes, T.
2003Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRHui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
2008Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaGiles, F.; DeAngelo, D.; Baccarani, M.; Deininger, M.; Guilhot, F.; Hughes, T.; Radich, J.; Ottmann, O.; Cortes, J.
2003Comments on the Hammersmith policyHughes, T.

Discover